Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Mission accepted.

In our media library you will find publications, videos and picture material about the CARL Technology, which document the current state of development and the performance of our products.

Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body: A Multicenter, Prospective Observational Study

Study published by the CARL-Centers Freiburg, Rotterdam, Linz, Regensburg, Düsseldorf, HH St. Georg and Bad Oeynhausen

To the study

CARL. in the Apotheken Umschau

In the February issue Apotheken Umschau, the CARL Technology and its mode of operation are presented under the title “Grenzen verschieben” by means of a detailed graphic.

To the article

Current publication on the application of the CARL. Technology at the Regensburg University Hospital

An article was published in the journal Perfusion in November 2022 presenting data from the first ten patients suffering from an out-of-hospital cardiovascular arrest who were treated by using the CARL Technology in Regensburg.

To the article

New press release

Dr. Thomas Kraft reinforces the management of Resuscitec GmbH

To the article

Recent Nature publication: Cellular recovery after prolonged warm ischaemia of the whole body

To the article

Presentation of the CARL. Technology during the visit of the Minister of the Interior Thomas Strobl at the Medical Center – University of Freiburg

Interior Minister Thomas Strobl has visited the Medical Center – University of Freiburg where the CARL Technology was presented.

To the article

CARL. -induced changes of the serum proteome

A recent publication in the Journal of Translational Medicine in May 2022 describes significant changes in serum protein composition after resuscitation using controlled extracorporeal circulation in pigs.

To the article

Current publication on the benefit of the CARL. Therapy

The Journal of Clinical Medicine recently published an article describing the benefits of adapted perfusion and defibrillation strategies in the setting of CARL Therapy.

To the article

Letter to the editor: Important factors regarding the analysis of extracorporeal blood flow in extracorporeal cardiopulmonary resuscitation.


To the article


An Invited Expert Opinion has been published in the Journal of Thoracic and Cardiovascular Surgery (JTCVS) on the use of cardiac surgical techniques to improve outcomes of cardiopulmonary resuscitation after cardiovascular arrest.

For more information on CARL Therapy, please visit: Therapy (resuscitec.de)

To the article

Thanks to CARL. – Larger time frame for successful resuscitation in cardiac arrest (text: German language)

The CARL Therapy developed by researchers of
The Medical Center – University of Freiburg and the mobile CARL Technology of Resuscitec GmbH provide a larger time window for the treatment of patients requiring resuscitation. An article published in “Ärztezeitung” in August,  2021 describes the therapeutic factors that are crucial for successful resuscitation even after prolonged cardiac arrest.

To the article >

‘Originally it was not planned to treat Covid patients at all’ (text: German language)

Interview with Prof. Dr.-Ing. Christoph Benk and Jörg Ronde, Managing Directors of Resuscitec GmbH in the VentureCapital Magazin

To the article >

New method of resuscitation: unharmed despite one-and-a-half hours of cardiac arrest (text: German language)

Just ten percent of those affected survive a cardiac arrest that happens outside a hospital – and only some of them without sequelae. A new method might change this. The ‘Neue Züricher Zeitung’ has published an article about CARL.

To the article >

Sudden cardiac arrest – Doc Fischer talks about CARL. in SWR-TV

It can happen to anyone at any time. Sudden cardiac arrest. The SWR-health programme ‘Doc Fischer’ explains the causes of sudden cardiac arrest, patient prevention possibilities and how the new second-line therapy CARL might improve survival rates further, both in-hospital and out-of-hospital.

Image: SWR

To the video >(minute 12:50)

Thanks to CARL.

In the following video, SWR reports on the success story of the therapy for CARL patient P. Kunzelmann.

To the video >

Imagefilm Resuscitec GmbH

The CARL Technology and its application possibilities

Format: mp4 Size: 540.85 MB

Another young life was saved – thanks to CARL.

A 36-year-old woman suffered a prolonged cardiac arrest lasting over one and a half hours. Only the use of CARL. enabled a successful resuscitation. The TV station SWR tells her story with CARL. in the following video (minute 13:12).

To the video >

CARL. Video

CARL product video

Format: mp4 Size: 127.60 MB

Abstract of the publication „Brain vulnerability and viability after ischemia” from the journal Nature Review Neuroscience

Professor Dr. Dr. h. c. Friedhelm Beyersdorf about the scientific basis of the CARL Therapy

Format: mp4 Size: 899.49 MB


Format: mov Size: 18.17 MB